| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 1506.1 | 1374.8 | 1232.3 |
| Other income | 13.0 | 14.7 | 12.4 |
| Total income | 1519.1 | 1389.5 | 1244.8 |
| Profit before exceptional items & tax | 311.0 | 281.1 | 174.7 |
| Exceptional items | 9.3 | 0.0 | 0.0 |
| Profit before tax | 320.3 | 281.1 | 174.7 |
| Net profit | 261.2 | 227.8 | 138.9 |
| Operating margin | 21.1% | 20.2% | 14.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +88.00% |
|---|---|
| Net profit, quarter on quarter | +14.70% |
| Revenue, year on year | +22.20% |
| Operating profit, year on year | +83.60% |
| Operating profit, quarter on quarter | +11.90% |
BSE results filing, NSE: SANDUMA. Figures extracted from the filing.
Sandur Manganese & Iron Ores Ltd: key numbers
- Share price
- ₹164.20
- Market cap
- ₹7,982 Cr
- Revenue (annual)
- ₹5,088 Cr
- Net profit (annual)
- ₹656.6 Cr
- P/E (TTM)
- 11.1×Sector 16.8×
- Promoter holding
- 74.22%+0.00% QoQ
- FII holding
- 1.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sandur Manganese & Iron Ores Ltd
All →Sandur Manganese & Iron Ores Management Change
Sandur Manganese appointed G. P. Kundargi as a Non-Executive Director from 12 November 2026, subject to shareholder approval. He brings mining and metals experience.
Sandur Manganese & Iron Ores Board Meeting Date
Sandur Manganese & Iron Ores will hold a board meeting on 3 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window is closed from 1 October 2026 until 48 hours after the meeting.
Sandur Manganese & Iron Ores Capacity Expansion
SMIORE's subsidiary Royal Sandur MedTech leased 6.2 acres at AP MedTech Zone, Visakhapatnam for a medical devices manufacturing unit. This marks the company's entry into the medical devices segment.
- Execution
- 33-year lease tenure
- land for medical devices manufacturing unit
- 6.2 acres
Sandur Manganese & Iron Ores Other Announcement
Sandur Manganese & Iron Ores Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, as required by SEBI regulations.
Sandur Manganese & Iron Ores Merger & Restructuring Worth ₹1 Cr
The Sandur Manganese & Iron Ores Ltd incorporated a new wholly owned subsidiary, Royal Sandur MedTech Private Limited, for medical devices and consumables manufacturing.
- Value
- ₹1.00 Cr
Sandur Manganese & Iron Ores Merger & Restructuring Worth ₹1 Cr
Sandur Manganese & Iron Ores approved the incorporation of a wholly-owned subsidiary, 'Royal Sandur MedTech Private Limited', with a capital investment of ₹1 Crore.
- Value
- ₹1.00 Cr